Med. praxi. 2024;21(5):302-305 | DOI: 10.36290/med.2024.027

Drugs with addiction potential

PharmDr. Ivana Tašková, PGDip
Oddělení klinické farmacie, Psychiatrická nemocnice Bohnice, Praha
Bezpečnost a kvalita léčiv, Farmaceutická fakulta, Masarykova univerzita, Brno

Drug abuse is a serious problem in the Czech Republic, affecting 8-13 % of the population. This phenomenon contributes to significant negative health, social, and economic consequences, including higher hospitalization rates and increased mortality. The most commonly abused and overused drugs are sedatives, hypnotics, and opioid analgesics, which are easily accessible and frequently prescribed medications, but also psychostimulants, antiepileptics, etc. This article focuses on analysing current trends in drug abuse in the Czech Republic, identifying at-risk groups, and managing dependency. Drug abuse is a serious problem among adolescents and young adults, and it is also more prevalent among patients with mental disorders and those suffering from chronic pain. Current measures to prevent abuse include educating healthcare professionals, monitoring prescriptions, and raising public awareness about the risks associated with drug overuse. Despite these measures, drug abuse is still on the rise, indicating a continuously increasing consumption of these risky medications. A more intensive approach and better coordination between healthcare, social, and legal institutions are needed. A long-term strategy should include a comprehensive approach, including legislative changes, expansion of preventive programs, and support for research in this area.

Keywords: drugs with addiction potential, opioid analgesics, benzodiazepines, stimulants.

Received: July 16, 2024; Revised: August 2, 2024; Accepted: August 5, 2024; Published: December 2, 2024  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Tašková I, PGDip. Drugs with addiction potential. Med. praxi. 2024;21(5):302-305. doi: 10.36290/med.2024.027.
Download citation
PDF will be unlocked 2.12.2025

References

  1. Národní monitorovací středisko pro drogy a závislosti: Souhrnná zpráva o závislostech 2023. Available from: https://www.drogy­‑info.cz/publikace/vyrocni­‑zpravy/souhrnna­‑zprava­‑o-zavislostech­‑v-ceske­‑republice-2023/.
  2. Národní monitorovací středisko pro drogy a závislosti: Zpráva o problematickém užívání psychoaktivních léků v České republice 2023. Available from: https://www.drogy­‑info.cz/publikace/vyrocni­‑zpravy/zprava­‑o-problematickem­‑uzivani­‑psychoaktivnich­‑leku­‑v-ceske­‑republice-2023/.
  3. Nutt D. Addiction. Oxford: Oxford psychiatric library. Oxford University Press; 2013. ISBN 978-0-19-968571-4.
  4. Cummins­‑Beebee PN, Chvilicek MM, Rothenfluh A. The Stage­‑Based Model of Addiction-Using Drosophila to Investigate Alcohol and Psychostimulant Responses. International Journal of Molecular Sciences. 2023;24(13):10909. https://doi.org/10.3390/ijms241310909. Go to original source... Go to PubMed...
  5. Bečková I, Višňovský P. Farmakologie drogových závislostí. Praha: Karolinum; 1999. ISBN 80-7184-864-6.
  6. Salzman C, et al. Benzodiazepine Dependence, Toxicity, and Abuse: A Task Force Report of the American Psychiatric Association. Published by: American Psychiatric Association Washington, DC; 1990. ISBN 0-89042-228-1. Go to original source...
  7. Wilkes S. The use of bupropion SR in cigarette smoking cessation. Int J Chron Obstruct Pulmon, DiS. 2008;3(1):45-53. doi: 10.2147/copd.s1121. PMID: 18488428; PMCID: PMC2528204. Go to original source... Go to PubMed...
  8. Mravčík V. Substituční léčba závislosti na opioidech v ČR: Kritický pohled. Česká a slovenská psychiatrie. 2019;115(2):53-58.
  9. Zhong G, Wang Y, Zhang Y, et al. Association between Benzodiazepine Use and Dementia: A Meta­‑Analysis. PLoS One. 2015 May 27;10(5):e0127836. doi: 10.1371/journal.pone.0127836. PMID: 26016483; PMCID: PMC4446315. Go to original source... Go to PubMed...
  10. S3-Leitlinie "Demenzen" (Langversion - Januar 2016). Available from: https://dnvp9c1uo2095.cloudfront.net/cms­‑content/S3-Leitlinie_Demenzen_Langversion_2023_11_28_Final_1701248604534.pdf.
  11. Wu CC, Liao MH, Su CH, et al. Benzodiazepine Use and the Risk of Dementia in the Elderly Population: An Umbrella Review of Meta­‑Analyses. J Pers Med. 2023 Oct 12;13(10):1485. doi: 10.3390/jpm13101485. PMID: 37888096; PMCID: PMC10608561. Go to original source... Go to PubMed...
  12. Oulis P, Konstantakopoulos G. Pregabalin in the Treatment of Alcohol and Benzodiazepines Dependence. CNS Neuroscience and Therapeutics. 2010;16:45-50. Go to original source... Go to PubMed...
  13. Park TW. Benzodiazepine use withdrawal. UpToDate 2024. Available from: www.uptodate.com.
  14. Chval J. Závislost na zolpidemu. Psychiatr. pro Praxi. 2009;10(5):239-240.
  15. Hrnčiarová J. Závislost u dospělých s poruchou pozornosti s hyperaktivitou (ADHD). Psychiatr. praxi. 2021;22(1):17-24. Go to original source...
  16. Bakouni H, Sharafi H, Bahremand A, et al. Bupropion for treatment of amphetamine­‑type stimulant use disorder: A systematic review and meta­‑analysis of placebo­‑controlled randomized clinical trials. Drug and Alcohol Dependence. 2023; 253. ISSN 0376-8716. Go to original source... Go to PubMed...
  17. Mohr P, et al. Klinická psychofarmakologie. Praha: Maxdorf; 2017: 441-443.
  18. Prášil V, Prášilová M. Pregabalin jako zneužívaná substance: kazuistiky léčby závislosti. Psychiatr. praxi. 2023;24(2):109-111. Go to original source...
  19. Ishikawa H, Takeshima M, Ishikawa H, et al. Pregabalin withdrawal in patients without psychiatric disorders taking a regular dose of pregabalin: A case series and literature review. Neuropsychopharmacol Rep. 2021 Sep;41(3):434-439. doi: 10.1002/npr2.12195. Epub 2021 Aug 12. PMID: 34382380; PMCID: PMC8411313. Go to original source... Go to PubMed...
  20. Bonnet U, Scherbaum N. Über das Abhängigkeitspotential von Gabapentinoiden [On the risk of dependence on gabapentinoids]. Fortschr Neurol Psychiatr. 2018 Feb;86(2):82-105. German. doi: 10.1055/s-0043-122392. Epub 2017 Nov 27. PMID: 29179227. Go to original source... Go to PubMed...
  21. Menšíková K, Nestrašil I, Praško JP. Behaviorální komplikace dopaminergní terapie v pokročilé fázi Parkinsonovy nemoci. Neurol. praxi. 2013;14(2):92-95.
  22. Espi Martinez F, Espi Forcen F, Shapov A, et al. Biperiden dependence: case report and literature review. Case Rep Psychiatry. 2012;2012:949256. doi: 10.1155/2012/949256. Epub 2012 May 30. PMID: 22937420; PMCID: PMC3420523. Go to original source... Go to PubMed...
  23. Wilson E, Lade, M.A. review of the management of antidepressant discontinuation symptoms. Ther Adv Psychopharmacol. 2015 Dec;5(6):357-68. doi: 10.1177/2045125315612334. PMID: 26834969; PMCID: PMC4722507. Go to original source... Go to PubMed...
  24. Alamo C, García­‑Garcia P, Lopez­‑Muñoz F, et al. Tianeptine, an atypical pharmacological approach to depression. Rev Psiquiatr Salud Ment (Engl Ed). 2019 Jul­‑Sep;12(3):170-186. English, Spanish. doi: 10.1016/j.rpsm.2018. 09. 002. Epub 2019 Jan 3. PMID: 30612921. Go to original source...
  25. Hýža M, Čechová M. Abúsus tianeptinu. Psychiatr. praxi. 2014;15(2):75-76.
  26. SPC léčivého přípravku Coaxil. Available from: www.sukl.cz.
  27. Kim S, Lee G, Kim E, Jung H, et al. J. Quetiapine Misuse and Abuse: Is it an Atypical Paradigm of Drug Seeking Behavior? J Res Pharm Pract. 2017 Jan­‑Mar;6(1):12-15. doi: 10.4103/2279-042X.200987. PMID: 28331860; PMCID: PMC5348850. Go to original source... Go to PubMed...




Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.